Anticancer

Ingenol 3-Angelate
Catalog No: CFN90924

Ingenol-3-angelate shows anticancer activity, and P-gp-mediated absorptive transport, dermal penetration, and vascular damage contribute to the anticancer activity of ingenol-3-angelate in vivo; it activates a broad range of PKC isoforms and induces apoptosis in acute myeloid leukemia cells by activating the PKC isoform PKCdelta. Ingenol-3-angelate suppresses HIV infection of primary CD4+ T cells through down-modulation of cell surface expression of HIV co-receptors. Ingenol-3-angelate emerges as a unique local chemotherapeutic immunostimulatory debulking agent that could be used in conjunction with immunotherapies to promote regression of metastases.

Escin IA
Catalog No: CFN93368

Escin IA is a prodrug and its structure can be converted to desacylescin I by human intestinal bacteria and Lactobacillus brevis., desacylescin I as a biotransformation product shows potentially inhibitory effects on mouse tumor, and a potential candidate for anti tumor agents. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression.

Desoxyrhaponticin
Catalog No: CFN90911

Desoxyrhaponticin is an agent that is potentially effective in controlling postprandial hyperglycemia in diabetes. Desoxyrhaponticin could be considered as a promising fatty acid synthase(FAS) inhibitor, it could inhibit intracellular FAS activity and downregulate FAS expression in human breast cancer MCF-7 cells.

Tubeimoside III
Catalog No: CFN90916

Tubeimoside III has anti-inflammatory, anti-tumor, and anti-tumorigenic activities, stronger than those of tubeimoside II. It has acute toxicity, stronger than that of tubeimoside II.

Tubeimoside II
Catalog No: CFN90915

Tubeimoside I, tubeimoside II, and tubeimoside III show anti-inflammatory, antitumor, and antitumor-promo ting effects.